Home>Topics>Stocks>Dendreon Corporation

Dendreon Corporation

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
  1. Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies

    Headlines

    Tue, 12 Aug 2014

    alongside chemotherapy, surgery, and radiation. Investors associate cancer immunotherapy with forerunner Dendreon Corporation (NASDAQ: DNDN ), whose PROVENGE vaccine shocked health plans with its exorbitant price that only extended life a few

  2. More on Dendreon Q2 results

    Headlines

    Tue, 12 Aug 2014

    Dendreon ( DNDN -33.5% ) Q2 results : Revenues: $82.2M (+12.1%); Operating Expenses: $83.9M (-34.7%); Net Loss

  3. Dendreon beats by $0.10, revenue in-line

    Headlines

    Tue, 12 Aug 2014

    Dendreon (NASDAQ: DNDN ): Q2 EPS of -$0.10 beats by $0.10 . Revenue of $82.2M (+12.1% Y/Y) in-line. Shares -22.6% PM. Press Release Post your comment!

  4. New Morningstar Analyst Report for Seattle Genetics Inc

    Stock Reports

    Fri, 1 Aug 2014

    in the investment community (given the recent failure of Dendreon 's pricey prostate cancer drug to live up to sales expectations ..... in the investment community following the recent failure of Dendreon 's DNDN pricey prostate cancer drug Provenge to live up to sales expectations

  5. Dendreon Receives Positive EU Opinion for Provenge; No Change to Fair Value Estimate or Moat Rating

    Commentary

    Fri, 28 Jun 2013

    Dendreon DNDN announced that it received a positive ..... Commission later this year, and we expect Dendreon to announce its commercialization plans ..... rating intact as we remain concerned about Dendreon 's ability to achieve meaningful commercial

  6. Provenge Sales Plummet in Dendreon's First Quarter

    Commentary

    Thu, 9 May 2013

    Dendreon DNDN reported dismal first-quarter results ..... prostate cancer space. Though we believe Dendreon 's first quarter will be a low-water ..... product revenue in the third quarter. Dendreon had $337.3 million in cash and investments

  7. Account Growth and Lower Costs Are Bright Spots in Dendreon's Third Quarter

    Commentary

    Fri, 2 Nov 2012

    deluge of negative developments over the last two years, Dendreon DNDN investors may finally be getting some good news in the firm ..... sequential basis. Despite continued slow Provenge sales traction, Dendreon 's cost-cutting efforts are beginning to take hold. The

  8. We're Substantially Lowering Our Outlook for Dendreon as Provenge Fails to Take Off

    Commentary

    Fri, 10 Aug 2012

    Sales of Dendreon 's DNDN sole marketed product Provenge are ..... downgrading our stewardship score for Dendreon to poor. Provenge's bungled launch ..... appropriate steps to try to right size Dendreon 's capacity to better match demand

  9. Dendreon Announces Large-Scale Restructuring on Heels of Slow Provenge Sales

    Commentary

    Tue, 31 Jul 2012

    Dendreon DNDN reported second-quarter results that ..... earlier this year--has exacerbated Dendreon 's preexisting commercialization challenges ..... trajectory, restructuring efforts should put Dendreon one step closer to profitability. Data

  10. Dendreon Sees Modest Sequential Growth for Provenge in 1Q; Firm Still in Range of Our 2012 Targets

    Commentary

    Tue, 8 May 2012

    Dendreon DNDN reported first-quarter results that ..... keeping our fair value estimate intact. Dendreon reported Provenge sales of $82.0 million ..... sales estimate of around $370 million. Dendreon outlined new efforts aimed at increasing

« Prev123Next »
Content Partners